[English] 日本語
Yorodumi
- EMDB-65160: Structure of human alpha-2/delta-1 with crisugabalin -

+
Open data


ID or keywords:

Loading...

-
Basic information

Entry
Database: EMDB / ID: EMD-65160
TitleStructure of human alpha-2/delta-1 with crisugabalin
Map data
Sample
  • Complex: Structure of human alpha-2/delta-1 with crisugabalin
    • Protein or peptide: Isoform 2 of Voltage-dependent calcium channel subunit alpha-2/delta-1
  • Ligand: 2-acetamido-2-deoxy-beta-D-glucopyranose
  • Ligand: Crisugabalin
KeywordsComplex / Alpha-2/delta-1 / Crisugabalin / MEMBRANE PROTEIN
Function / homology
Function and homology information


regulation of membrane repolarization during action potential / calcium ion transmembrane transport via high voltage-gated calcium channel / membrane depolarization during bundle of His cell action potential / L-type voltage-gated calcium channel complex / regulation of ventricular cardiac muscle cell membrane repolarization / cardiac muscle cell action potential involved in contraction / calcium ion transport into cytosol / regulation of calcium ion transmembrane transport via high voltage-gated calcium channel / voltage-gated calcium channel complex / Mechanical load activates signaling by PIEZO1 and integrins in osteocytes ...regulation of membrane repolarization during action potential / calcium ion transmembrane transport via high voltage-gated calcium channel / membrane depolarization during bundle of His cell action potential / L-type voltage-gated calcium channel complex / regulation of ventricular cardiac muscle cell membrane repolarization / cardiac muscle cell action potential involved in contraction / calcium ion transport into cytosol / regulation of calcium ion transmembrane transport via high voltage-gated calcium channel / voltage-gated calcium channel complex / Mechanical load activates signaling by PIEZO1 and integrins in osteocytes / regulation of heart rate by cardiac conduction / calcium ion import across plasma membrane / regulation of calcium ion transport / neuronal dense core vesicle / voltage-gated calcium channel activity / presynaptic active zone membrane / sarcoplasmic reticulum / GABA-ergic synapse / cellular response to amyloid-beta / calcium ion transport / extracellular exosome / metal ion binding / plasma membrane
Similarity search - Function
VWA N-terminal / Voltage-dependent calcium channel, alpha-2/delta subunit, conserved region / VWA N-terminal / Neuronal voltage-dependent calcium channel alpha 2acd / : / von Willebrand factor type A domain / VWFA domain profile. / von Willebrand factor (vWF) type A domain / von Willebrand factor, type A / von Willebrand factor A-like domain superfamily
Similarity search - Domain/homology
Voltage-dependent calcium channel subunit alpha-2/delta-1
Similarity search - Component
Biological speciesHomo sapiens (human)
Methodsingle particle reconstruction / cryo EM / Resolution: 3.01 Å
AuthorsWang J / Chen Z / Gou X
Funding support1 items
OrganizationGrant numberCountry
Not funded
CitationJournal: J Chem Inf Model / Year: 2026
Title: Structural and Computational Insights into the Mechanism of the Superior Pharmacological Activity of Crisugabalin: A Third-Generation Cavαδ1 Ligand.
Authors: Zhaoqiang Chen / Xiaoli Gou / Qingyuan Meng / He Li / Yao Li / Zongjun Shi / Xinxin Li / Ju Wang /
Abstract: Crisugabalin, a recently approved third-generation GABA analogue with a unique cage-like tricyclic scaffold, shows superior efficacy and safety over pregabalin and mirogabalin for treating ...Crisugabalin, a recently approved third-generation GABA analogue with a unique cage-like tricyclic scaffold, shows superior efficacy and safety over pregabalin and mirogabalin for treating neuropathic pain. Through integrated biophysical, structural, and computational approaches, we elucidate the molecular basis of its enhanced pharmacological profile. Dissociation kinetic studies revealed that crisugabalin exhibited the slowest dissociation kinetics from the αδ1 subunit (τ = 32.05, 80.00, 111.11 min for pregabalin, mirogabalin, and crisugabalin) but the fastest dissociation from the αδ2 subunit (τ = 8.70, 16.39, 5.78 min for pregabalin, mirogabalin, and crisugabalin). Cryo-EM structures demonstrated crisugabalin's superior binding affinity for αδ1 over gabapentin and l-leucine, driven by enhanced hydrogen bonding and hydrophobic contacts, alongside volumetric expansion of the l-leucine binding pocket. Molecular dynamics (MD) simulations identified significantly more persistent hydrogen bonding by crisugabalin (66.3% average occupancy) relative to pregabalin (28.3%). Random Acceleration Molecular Dynamics (RAMD) simulations revealed that ligand dissociation primarily proceeds via Pathway A (along the β2, β3, and β1 segments), and τRAMD calculations correctly ranked the ligand residence times, yielding values of 0.18 ns for pregabalin and 2.88 ns for crisugabalin. Furthermore, the binding free energies for pregabalin, mirogabalin, and crisugabalin were -21.64, -31.30, and -34.99 kcal/mol, calculated by MM/GBSA. The decomposition of the binding free energy components revealed that crisugabalin exhibits a dual-action mechanism characterized by enhanced hydrophobic interactions (-28.46 kcal/mol) and favorable entropic contributions (3.03 kcal/mol). This unique binding behavior stems from its cage-like tricyclic scaffold, an unprecedented substructure in drug molecules. These findings establish the cage-like tricyclic motif as a novel pharmacophore that simultaneously optimizes binding entropy and enthalpy, providing a blueprint for next-generation voltage-gated calcium channel modulators. MD, τRAMD, and MM-GBSA used in this study are powerful computational tools for rational drug design, particularly for optimizing compounds with prolonged target residence times.
History
DepositionJun 25, 2025-
Header (metadata) releaseJan 7, 2026-
Map releaseJan 7, 2026-
UpdateJan 7, 2026-
Current statusJan 7, 2026Processing site: PDBc / Status: Released

-
Structure visualization

Supplemental images

Downloads & links

-
Map

FileDownload / File: emd_65160.map.gz / Format: CCP4 / Size: 91.1 MB / Type: IMAGE STORED AS FLOATING POINT NUMBER (4 BYTES)
Projections & slices

Image control

Size
Brightness
Contrast
Others
AxesZ (Sec.)Y (Row.)X (Col.)
0.82 Å/pix.
x 288 pix.
= 235.872 Å
0.82 Å/pix.
x 288 pix.
= 235.872 Å
0.82 Å/pix.
x 288 pix.
= 235.872 Å

Surface

Projections

Slices (1/3)

Slices (1/2)

Slices (2/3)

Images are generated by Spider.

Voxel sizeX=Y=Z: 0.819 Å
Density
Contour LevelBy AUTHOR: 0.08
Minimum - Maximum-0.16707972 - 0.35724485
Average (Standard dev.)-0.00030034655 (±0.009367353)
SymmetrySpace group: 1
Details

EMDB XML:

Map geometry
Axis orderXYZ
Origin000
Dimensions288288288
Spacing288288288
CellA=B=C: 235.87201 Å
α=β=γ: 90.0 °

-
Supplemental data

-
Mask #1

Fileemd_65160_msk_1.map
Projections & Slices
AxesZYX

Projections

Slices (1/2)
Density Histograms

-
Additional map: cryoSPARC sharpened map

Fileemd_65160_additional_1.map
AnnotationcryoSPARC sharpened map
Projections & Slices
AxesZYX

Projections

Slices (1/2)
Density Histograms

-
Half map: #1

Fileemd_65160_half_map_1.map
Projections & Slices
AxesZYX

Projections

Slices (1/2)
Density Histograms

-
Half map: #2

Fileemd_65160_half_map_2.map
Projections & Slices
AxesZYX

Projections

Slices (1/2)
Density Histograms

-
Sample components

-
Entire : Structure of human alpha-2/delta-1 with crisugabalin

EntireName: Structure of human alpha-2/delta-1 with crisugabalin
Components
  • Complex: Structure of human alpha-2/delta-1 with crisugabalin
    • Protein or peptide: Isoform 2 of Voltage-dependent calcium channel subunit alpha-2/delta-1
  • Ligand: 2-acetamido-2-deoxy-beta-D-glucopyranose
  • Ligand: Crisugabalin

-
Supramolecule #1: Structure of human alpha-2/delta-1 with crisugabalin

SupramoleculeName: Structure of human alpha-2/delta-1 with crisugabalin / type: complex / ID: 1 / Parent: 0 / Macromolecule list: #1
Source (natural)Organism: Homo sapiens (human)

-
Macromolecule #1: Isoform 2 of Voltage-dependent calcium channel subunit alpha-2/delta-1

MacromoleculeName: Isoform 2 of Voltage-dependent calcium channel subunit alpha-2/delta-1
type: protein_or_peptide / ID: 1 / Number of copies: 1 / Enantiomer: LEVO
Source (natural)Organism: Homo sapiens (human)
Molecular weightTheoretical: 120.990766 KDa
Recombinant expressionOrganism: Homo sapiens (human)
SequenceString: HHHHHHHHWS HPQFEKEPFP SAVTIKSWVD KMQEDLVTLA KTASGVNQLV DIYEKYQDLY TVEPNNARQL VEIAARDIEK LLSNRSKAL VRLALEAEKV QAAHQWREDF ASNEVVYYNA KDDLDPEKND SEPGSQRIKP VFIEDANFGR QISYQHAAVH I PTDIYEGS ...String:
HHHHHHHHWS HPQFEKEPFP SAVTIKSWVD KMQEDLVTLA KTASGVNQLV DIYEKYQDLY TVEPNNARQL VEIAARDIEK LLSNRSKAL VRLALEAEKV QAAHQWREDF ASNEVVYYNA KDDLDPEKND SEPGSQRIKP VFIEDANFGR QISYQHAAVH I PTDIYEGS TIVLNELNWT SALDEVFKKN REEDPSLLWQ VFGSATGLAR YYPASPWVDN SRTPNKIDLY DVRRRPWYIQ GA ASPKDML ILVDVSGSVS GLTLKLIRTS VSEMLETLSD DDFVNVASFN SNAQDVSCFQ HLVQANVRNK KVLKDAVNNI TAK GITDYK KGFSFAFEQL LNYNVSRANC NKIIMLFTDG GEERAQEIFN KYNKDKKVRV FTFSVGQHNY DRGPIQWMAC ENKG YYYEI PSIGAIRINT QEYLDVLGRP MVLAGDKAKQ VQWTNVYLDA LELGLVITGT LPVFNITGQF ENKTNLKNQL ILGVM GVDV SLEDIKRLTP RFTLCPNGYY FAIDPNGYVL LHPNLQPKNP KSQEPVTLDF LDAELENDIK VEIRNKMIDG ESGEKT FRT LVKSQDERYI DKGNRTYTWT PVNGTDYSLA LVLPTYSFYY IKAKLEETIT QARSKKGKMK DSETLKPDNF EESGYTF IA PRDYCNDLKI SDNNTEFLLN FNEFIDRHHH HHHHHKTPNN PSCNADLINR VLLDAGFTNE LVQNYWSKQK NIKGVKAR F VVTDGGITRV YPKEAGENWQ ENPETYEDSF YKRSLDNDNY VFTAPYFNKS GPGAYESGIM VSKAVEIYIQ GKLLKPAVV GIKIDVNSWI ENFTKTSIRD PCAGPVCDCK RNSDVMDCVI LDDGGFLLMA NHDDYTNQIG RFFGEIDPSL MRHLVNISVY AFNKSYDYQ SVCEPGAAPK QGAGHRSAYV PSVADILQIG WWATAAAWSI LQQFLLSLTF PRLLEAVEME DDDFTASLSK Q SCITEQTQ YFFDNDSKSF SGVLDCGNCS RIFHGEKLMN TNLIFIMVES KGTCPCDTRL LIQAEQTSDG PNPCDMVKQP RY RKGPDVC FDNNVLEDYT DCGGVSG

UniProtKB: Voltage-dependent calcium channel subunit alpha-2/delta-1

-
Macromolecule #4: 2-acetamido-2-deoxy-beta-D-glucopyranose

MacromoleculeName: 2-acetamido-2-deoxy-beta-D-glucopyranose / type: ligand / ID: 4 / Number of copies: 2 / Formula: NAG
Molecular weightTheoretical: 221.208 Da
Chemical component information

ChemComp-NAG:
2-acetamido-2-deoxy-beta-D-glucopyranose

-
Macromolecule #5: Crisugabalin

MacromoleculeName: Crisugabalin / type: ligand / ID: 5 / Number of copies: 1 / Formula: A1ESQ
Molecular weightTheoretical: 209.285 Da

-
Experimental details

-
Structure determination

Methodcryo EM
Processingsingle particle reconstruction
Aggregation stateparticle

-
Sample preparation

BufferpH: 7.5
VitrificationCryogen name: ETHANE / Chamber humidity: 100 %

-
Electron microscopy

MicroscopeFEI/PHILIPS CM300FEG/HE
Image recordingFilm or detector model: GATAN K3 BIOCONTINUUM (6k x 4k) / Average electron dose: 55.0 e/Å2
Electron beamAcceleration voltage: 300 kV / Electron source: FIELD EMISSION GUN
Electron opticsIllumination mode: FLOOD BEAM / Imaging mode: BRIGHT FIELD / Nominal defocus max: 1.8 µm / Nominal defocus min: 1.1 µm

+
Image processing

CTF correctionType: NONE
Startup modelType of model: PDB ENTRY
PDB model - PDB ID:
Final reconstructionResolution.type: BY AUTHOR / Resolution: 3.01 Å / Resolution method: FSC 0.143 CUT-OFF / Software - Name: cryoSPARC / Number images used: 226483
Initial angle assignmentType: MAXIMUM LIKELIHOOD
Final angle assignmentType: MAXIMUM LIKELIHOOD
FSC plot (resolution estimation)

+
About Yorodumi

-
News

-
Feb 9, 2022. New format data for meta-information of EMDB entries

New format data for meta-information of EMDB entries

  • Version 3 of the EMDB header file is now the official format.
  • The previous official version 1.9 will be removed from the archive.

Related info.:EMDB header

External links:wwPDB to switch to version 3 of the EMDB data model

-
Aug 12, 2020. Covid-19 info

Covid-19 info

URL: https://pdbj.org/emnavi/covid19.php

New page: Covid-19 featured information page in EM Navigator.

Related info.:Covid-19 info / Mar 5, 2020. Novel coronavirus structure data

+
Mar 5, 2020. Novel coronavirus structure data

Novel coronavirus structure data

Related info.:Yorodumi Speices / Aug 12, 2020. Covid-19 info

External links:COVID-19 featured content - PDBj / Molecule of the Month (242):Coronavirus Proteases

+
Jan 31, 2019. EMDB accession codes are about to change! (news from PDBe EMDB page)

EMDB accession codes are about to change! (news from PDBe EMDB page)

  • The allocation of 4 digits for EMDB accession codes will soon come to an end. Whilst these codes will remain in use, new EMDB accession codes will include an additional digit and will expand incrementally as the available range of codes is exhausted. The current 4-digit format prefixed with “EMD-” (i.e. EMD-XXXX) will advance to a 5-digit format (i.e. EMD-XXXXX), and so on. It is currently estimated that the 4-digit codes will be depleted around Spring 2019, at which point the 5-digit format will come into force.
  • The EM Navigator/Yorodumi systems omit the EMD- prefix.

Related info.:Q: What is EMD? / ID/Accession-code notation in Yorodumi/EM Navigator

External links:EMDB Accession Codes are Changing Soon! / Contact to PDBj

+
Jul 12, 2017. Major update of PDB

Major update of PDB

  • wwPDB released updated PDB data conforming to the new PDBx/mmCIF dictionary.
  • This is a major update changing the version number from 4 to 5, and with Remediation, in which all the entries are updated.
  • In this update, many items about electron microscopy experimental information are reorganized (e.g. em_software).
  • Now, EM Navigator and Yorodumi are based on the updated data.

External links:wwPDB Remediation / Enriched Model Files Conforming to OneDep Data Standards Now Available in the PDB FTP Archive

-
Yorodumi

Thousand views of thousand structures

  • Yorodumi is a browser for structure data from EMDB, PDB, SASBDB, etc.
  • This page is also the successor to EM Navigator detail page, and also detail information page/front-end page for Omokage search.
  • The word "yorodu" (or yorozu) is an old Japanese word meaning "ten thousand". "mi" (miru) is to see.

Related info.:EMDB / PDB / SASBDB / Comparison of 3 databanks / Yorodumi Search / Aug 31, 2016. New EM Navigator & Yorodumi / Yorodumi Papers / Jmol/JSmol / Function and homology information / Changes in new EM Navigator and Yorodumi

Read more